pretickt

Is DXCM a good stock to buy?

DexCom, Inc. · end-of-day data as of Nov 13, 2026

Dexcom
DXCM · $31.08B
$83.33+2.4%
Nov 13, 2026 · close
$80$90SepOctNov9:3016:003 months -7.0%Nov 13 · close
▲ 6
  • PT$94.75 +13.7%
  • ConsensusBuy · 29
  • News
  • MAs3 of 4
  • MACD0.17
  • Sector▲ +15.9%
Neutral
  • Earnings in90d
  • P/E32.7x
  • RSI51
  • Support-1.2%
  • Resistance+4.6%
  • Off 52w high-10.0%
  • Volume0.6x
  • Bollingerupper half
  • FCF yield+3.5%
  • P/E vs own+9.9%
  • P/E vs sector+1.4%
  • Trendsideways
  • 52w range$57–$93
  • ATR+3.6%
  • Off ATH-49.5%
▼ 1
  • Insiders-$4.33M

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Dexcom a good stock to buy?

Dexcom is strong on 3 of the 5 questions about the business. The price is low: 32.7 times its earnings, below its 3-year median of 45.5 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage some edge
  3. Economics very profitable
  4. Execution mixed
  5. Fragility sturdy
  6. Price below its usual
DemandDo people want more of what it sells?growing

DXCM sales growth revenue growth

+17%a year, for the last 3 years

Dexcom's sales grew 17% a year for 3 years, to $4.66B in fiscal 2025.

DXCM analysts' forecast revenue estimates

+12%the sales they expect next fiscal year, on the last

Analysts expect Dexcom's sales to grow 12% to $5.23B in fiscal 2026 (21 analysts).

DXCM competitors

pretickt analysis+13%its sales in 12 months, on a year before

Dexcom's sales grew 13% in the 12 months to Sep 30, 2026, faster than Boston Scientific (+9%), Zimmer Biomet (+7%) and GE HealthCare (+2%), slower than Edwards Lifesciences (+13%).

Advantage moatIs it hard to copy?some edge

DXCM return on capital ROIC

pretickt analysis41%earned before tax on the money invested in it

Dexcom earned 41% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Edwards Lifesciences 16%, GE HealthCare 14%, Boston Scientific 12% and Zimmer Biomet 7%.

DXCM margin on each sale gross margin

63%left after making the product

Dexcom kept 63% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 70%.

EconomicsDoes it make good money?very profitable

DXCM margin after costs profit margin

24%of sales left after running the business

Dexcom's operating margin was 24% in the 12 months to Sep 30, 2026, against 13% in fiscal 2022.

DXCM cash generated free cash flow

$1.1Bcash left after investing, last 12 months

Dexcom generated $1.1B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

DXCM profit per share

+47%in its last fiscal year

Dexcom's earnings per share grew 47% in fiscal 2025, to $2.10.

ExecutionDoes it deliver what it promises?mixed

DXCM earnings vs estimates

6 of 8quarters above the analysts' estimate

Dexcom beat the analysts' profit estimate in 6 of its last 8 quarters, the latest on Oct 29, 2026.

DXCM insider selling

-$12.69Msold, net, by its executives in 12 months

Dexcom's executives and directors sold a net $12.69M of shares in the 12 months to Nov 13, 2026; none bought.

DXCM CEO pay

$7.99Mfor fiscal 2025, 74% of it in stock and options

Dexcom paid its CEO $7.99M for fiscal 2025, 74% of it in stock and options.

Fragility risksCould something break it?sturdy

DXCM financial health Altman Z-score

7.6Altman Z-score, safe above 3

Dexcom's Altman Z-score is 7.6 (Nov 13, 2026), above 3, where the safe zone starts.

DXCM quality checks Piotroski score

8 of 9checks passed

Dexcom passes 8 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on long-term debt.

DXCM in past recessions

pretickt analysis+31%its sales in the worst one

Dexcom's sales grew through each of the last 2 US recessions (2008–09 and 2020).

Price valuationIs the price reasonable?below its usual

DXCM price vs profit P/E ratio

32.7×a year's earnings

Dexcom's P/E ratio is 32.7 (Nov 13, 2026), below its 3-year median of 45.5.

DXCM price vs competitors

pretickt analysis32.7×a year's earnings, against its competitors

Investors pay 32.7 times Dexcom's earnings (Nov 13, 2026), more than for Zimmer Biomet (26.1), GE HealthCare (21.7) and Boston Scientific (18.8), less than for Edwards Lifesciences (60.5).

DXCM analysts' target price target

+14%to their average target

Analysts' average price target for Dexcom is $94.75, 14% above the Nov 13, 2026 close of $83.33.

DXCM growth priced in fair value

pretickt analysis+12%a year, for ten years, to be worth the price

At $83.33 a share, Dexcom's free cash flow must grow about 12% a year for ten years to be worth the price (Nov 13, 2026).

What is Dexcom's P/E ratio?

Dexcom's P/E ratio is 32.7 (Nov 13, 2026), below its 3-year median of 45.5. Investors pay 32.7 times Dexcom's earnings (Nov 13, 2026), more than for Zimmer Biomet (26.1), GE HealthCare (21.7) and Boston Scientific (18.8), less than for Edwards Lifesciences (60.5).

Who are Dexcom's biggest competitors?

pretickt compares Dexcom with GE HealthCare, Zimmer Biomet, Edwards Lifesciences and Boston Scientific. Dexcom's sales grew 13% in the 12 months to Sep 30, 2026, faster than Boston Scientific (+9%), Zimmer Biomet (+7%) and GE HealthCare (+2%), slower than Edwards Lifesciences (+13%).

Is Dexcom profitable?

Dexcom's operating margin was 24% in the 12 months to Sep 30, 2026, against 13% in fiscal 2022. Dexcom generated $1.1B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

Are insiders selling Dexcom stock?

Dexcom's executives and directors sold a net $12.69M of shares in the 12 months to Nov 13, 2026; none bought.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.